Logo image of APLI.CA

APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Fundamental Analysis

TSX:APLI - Toronto Stock Exchange - CA03783R1073 - Common Stock - Currency: CAD

0.015  0 (0%)

Fundamental Rating

0

Taking everything into account, APLI scores 0 out of 10 in our fundamental rating. APLI was compared to 35 industry peers in the Pharmaceuticals industry. APLI may be in some trouble as it scores bad on both profitability and health. APLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APLI has reported negative net income.
In the past year APLI has reported a negative cash flow from operations.
In the past 5 years APLI always reported negative net income.
APLI had a negative operating cash flow in each of the past 5 years.
APLI.CA Yearly Net Income VS EBIT VS OCF VS FCFAPLI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -188.96%, APLI is doing worse than 94.29% of the companies in the same industry.
Industry RankSector Rank
ROA -188.96%
ROE N/A
ROIC N/A
ROA(3y)-284.09%
ROA(5y)-195.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APLI.CA Yearly ROA, ROE, ROICAPLI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APLI.CA Yearly Profit, Operating, Gross MarginsAPLI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

APLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APLI has about the same amount of shares outstanding.
Compared to 5 years ago, APLI has more shares outstanding
The debt/assets ratio for APLI is higher compared to a year ago.
APLI.CA Yearly Shares OutstandingAPLI.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLI.CA Yearly Total Debt VS Total AssetsAPLI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

APLI has an Altman-Z score of -70.26. This is a bad value and indicates that APLI is not financially healthy and even has some risk of bankruptcy.
APLI's Altman-Z score of -70.26 is on the low side compared to the rest of the industry. APLI is outperformed by 97.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -70.26
ROIC/WACCN/A
WACC10.9%
APLI.CA Yearly LT Debt VS Equity VS FCFAPLI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

APLI has a Current Ratio of 0.14. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
APLI has a worse Current ratio (0.14) than 94.29% of its industry peers.
APLI has a Quick Ratio of 0.14. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.14, APLI is not doing good in the industry: 94.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14
APLI.CA Yearly Current Assets VS Current LiabilitesAPLI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.07% over the past year.
APLI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -89.13%.
EPS 1Y (TTM)21.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-230.77%
Revenue 1Y (TTM)-89.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-77.6%

3.2 Future

The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APLI.CA Yearly Revenue VS EstimatesAPLI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 200K 400K 600K 800K 1M
APLI.CA Yearly EPS VS EstimatesAPLI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 0 0 0 0

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

APLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLI.CA Price Earnings VS Forward Price EarningsAPLI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLI.CA Per share dataAPLI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPILI THERAPEUTICS INC-CL A

TSX:APLI (6/6/2025, 7:00:00 PM)

0.015

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-18 2025-02-18
Earnings (Next)06-25 2025-06-25/amc
Inst Owners11.84%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap1.82M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -188.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-284.09%
ROA(5y)-195.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.52%
Cap/Sales 1.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z -70.26
F-Score3
WACC10.9%
ROIC/WACCN/A
Cap/Depr(3y)72.26%
Cap/Depr(5y)63.36%
Cap/Sales(3y)1.2%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-230.77%
EPS Next Y0%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-89.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-77.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y95.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y95.16%
OCF growth 3YN/A
OCF growth 5YN/A